Loading...
•
Dec 31, 2023
Mirum Pharmaceuticals Q4 2023 Earnings Report
Mirum Pharmaceuticals reported fourth quarter and year-end 2023 financial results.
Key Takeaways
Mirum Pharmaceuticals reported net product sales of $178.9 million for the full year 2023, representing 142% growth over 2022.
Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue.
2023 LIVMARLI net product sales totaled $141.8 million, representing approximately 89% growth over 2022 net product sales.
International business grew to 18 countries with reimbursed access to LIVMARLI.
FDA Prescription Drug User Free Act (PDUFA) date for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) is March 13, 2024.
Revenue by Segment
Forward Guidance
Mirum Pharmaceuticals expects continued revenue growth across all approved medicines in 2024 with expected global net product sales of $310 million to $320 million.
Positive Outlook
- Continued revenue growth across all approved medicines is expected in 2024.
- Expected global net product sales of $310 million to $320 million in 2024.
- LIVMARLI PFIC PDUFA date on track for March 13, 2024.
- New Drug Application (NDA) submission for CHENODAL in CTX planned in first half 2024.
- Volixibat VISTAS and VANTAGE interim analyses expected in first half of 2024
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...